Hypertension Monitoring in Glioma Patients Treated With Bevacizumab
Hypertension Monitoring in Glioma Patients Treated With Bevacizumab
Prospective casecontrol study in glioma patients undergoing treatment with bevacizumab
 (Avastin). At present there are no data on the correlation between occurrence of arterial
 hypertension and clinical outcome in patients with glioma or anaplastic astrocytoma. We will
 investigate whether glioma patients developing hypertension under bevacizumab treatment have
 a better outcome in terms of progression free survival, response rate and overall survival
 than equally treated patients remaining normotensive. Moreover, we will describe the dynamics
 of change in blood pressure after administration of bevacizumab in those patients developing
 hypertension.

 -  Trial with medicinal product
Inclusion criteria: Patients aged 18 or older with histological diagnosis of anaplastic
 astrocytoma (WHO grade III) or glioma (WHO grade IV) Assigned to bevacizumab treatment
 (monotherapy or adjunctive to chemotherapy) for therapeutic reasons by an oncologist
 Patients should be on a stable or decreasing dose of steroids Willingness and ability to
 comply with the protocol Patient should present with a KPS of >=70 Signed informed consent

 Exclusion criteria: Previous anti-angiogenic drugs other than bevacizumab Allergy or
 hypersensitivity against bevacizumab Contraindications to bevacizumab according to the
 Summary of Product of Characteristics Unwillingness to comply with regular assessments of
 response and performance of study-related procedures Any condition considered relevant for
 proper performance of the study or risk to the patients, at the discretion of the
 investigator